Agarwal and colleagues present an analysis of the overlap in the drug targets that are being pursued across the industry, which indicates that more than half of the novel drug targets in current pipelines are being pursued by only one company.
- Pankaj Agarwal
- Philippe Sanseau
- Lon R. Cardon